Canagliflozin outperforms sitagliptin in diabetes study

06/28/2013 | Family Practice News

Data on 1,020 metformin-treated type 2 diabetes patients revealed those who took canagliflozin attained lower fasting plasma glucose and showed greater improvements in glycemic control, body weight and blood pressure at 52 weeks than those who either took sitagliptin or placebo followed by sitagliptin. However, canagliflozin was linked to higher rates of genital mycotic infections and adverse events related to osmotic diuresis compared with the other treatments, researchers reported at the ADA 73rd Scientific Sessions.

View Full Article in:

Family Practice News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC